Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Hamburg Era Begins At FDA: NEJM Editorial Faces Critics Head-On, May Buy Breathing Room

Executive Summary

FDA Commissioner Margaret Hamburg is getting a quick start on rebuilding the agency's public health credentials

You may also be interested in...

Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Sen. Alexander and others remain optimistic as several holds and a filibuster threat emerge.

FDA Outreach To Physicians On LABAs Shows Challenges Of Safety Strategy

FDA appears to have settled on a mechanism for explaining its policy decisions to the physician community: publishing articles in The New England Journal of Medicine. Whether the strategy can produce the desired results remains less clear

The State of New Drug Reviews in the US

Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts